Sara M. Tolaney, MD, MPH, reflects on a patient who had metastatic triple-negative breast cancer and a germline BRCA mutation and was seeking enrollment in a clinical trial.
The patient had a great response and moved on to more clinical trials with novel therapies that targeted her homologous recombination deficiency, achieving an 8-year duration of response. The patient was able to see all of her children graduate from high school, a testament to the impact of these novel and emerging therapies and the understanding of an individual patient's tumor biology.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Achieving a Long Duration of Response in Metastatic Breast Cancer Through Powerful Novel Therapies - Medscape - Jan 06, 2023.
Comments